Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen Sells 1,523 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen sold 1,523 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.44, for a total value of $49,406.12. Following the completion of the transaction, the chief financial officer now owns 110,500 shares in the company, valued at approximately $3,584,620. This trade represents a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ionis Pharmaceuticals Trading Up 0.7 %

Ionis Pharmaceuticals stock traded up $0.23 during midday trading on Monday, reaching $32.13. 1,662,595 shares of the stock traded hands, compared to its average volume of 1,661,709. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. The firm has a market cap of $5.07 billion, a PE ratio of -13.17 and a beta of 0.35. The company has a 50-day simple moving average of $35.07 and a two-hundred day simple moving average of $40.00. Ionis Pharmaceuticals, Inc. has a 12-month low of $31.03 and a 12-month high of $52.34.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after buying an additional 303 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Ionis Pharmaceuticals during the third quarter worth about $40,000. Prospera Private Wealth LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $42,000. Itau Unibanco Holding S.A. raised its holdings in Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after acquiring an additional 314 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Ionis Pharmaceuticals in the third quarter worth approximately $51,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on IONS. Wells Fargo & Company decreased their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Guggenheim decreased their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 15th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.